Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil

N Engl J Med. 2023 Jul 13;389(2):188-190. doi: 10.1056/NEJMc2304157.
No abstract available

Publication types

  • Letter

MeSH terms

  • Acetamides
  • Antineoplastic Agents* / therapeutic use
  • Carcinoma, Squamous Cell* / drug therapy
  • Humans
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / adverse effects
  • Skin Neoplasms* / drug therapy

Substances

  • Acetamides
  • Antineoplastic Agents
  • belumosudil
  • Pyrazoles
  • ruxolitinib
  • Protein Kinase Inhibitors